Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 126 Results

Title
Intervention Indication Therapeutic Area Year Actions
Fedratinib for Myelofibrosis Fedratinib (SAR302503) Myelofibrosis Haematological Cancer and Lymphomas , Haematology 2018 View  |  Download
Gilteritinib for Relapsed or Refractory Acute Myeloid Leukaemia (AML) with an FLT3 Mutation – Second Line Gilteritinib (ASP2215; Xospata; gilteritinib fumarate) Acute myeloid leukaemia (AML) Haematological Cancer and Lymphomas 2018 View  |  Download
Gilteritinib maintenance therapy for FLT3-ITD mutated acute myeloid leukaemia Gilteritinib (ASP2215; Xospata; gilteritinib fumarate) Acute myeloid leukaemia (AML) Haematological Cancer and Lymphomas 2022 View  |  Download
Glasdegib for Acute Myeloid Leukaemia (AML) – first line Glasdegib (PF-04449913; glasdegib maleate) Acute myeloid leukaemia (AML) Haematological Cancer and Lymphomas 2017 View  |  Download
Glofitamab for relapsed or refractory diffuse large B-cell lymphoma Glofitamab (RG-6026) Diffuse large B-cell lymphoma (DLBCL) , High grade B cell lymphoma (HGBCL) , Primary mediastinal large B-cell lymphoma (PMBCL) Haematological Cancer and Lymphomas 2021 View  |  Download
Glofitamab with gemcitabine, oxaliplatin and rituximab for treating relapsed or refractory diffuse large B-cell lymphoma Gemcitabine (Gemzar; gemcitabine hydrochloride) , Glofitamab (RG-6026) , Oxaliplatin , Rituximab (MabThera; Rituxan; RG 105) Diffuse large B-cell lymphoma (DLBCL) Haematological Cancer and Lymphomas 2022 View  |  Download
Guadecitabine for Treatment of Naive Acute Myeloid Leukaemia Guadecitabine (SGI-110) Acute myeloid leukaemia (AML) Haematological Cancer and Lymphomas 2017 View  |  Download
Histamine dihydrochloride (Ceplene) in combination with low dose interleukin-2 as maintenance treatment for acute myeloid leukaemia Histamine dihydrochloride (Ceplene) , Low-dose aldesluekin Acute myeloid leukaemia (AML) Haematological Cancer and Lymphomas 2019 View  |  Download
Ibrutinib for the treatment of relapsed or refractory follicular lymphoma Ibrutinib (Imbruvica) Follicular lymphoma Haematological Cancer and Lymphomas 2017 View  |  Download
Ibrutinib in addition to rituximab for chronic lymphocytic leukaemia – first-line Ibrutinib (Imbruvica) Chronic lymphocytic leukaemia (CLL) Haematological Cancer and Lymphomas 2019 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications